Eric Klein from the Cleveland Clinic is presenting the prostate CA poster. This product could be GH's most important. To see what this guy is researching, watch his video in the link below. I found it interesting.
I agree his research is very important..." improve discrimination clinically aggressive from indolent prostate cancer" this is reason GHDX test can be potentially hugh market...no wonder Bakers are BUYING BUYING & BUYING...practically every week on dip....they are not just accumulating for M&A..